Funded Tech Companies

Amplo Biotechnology

Amplo Biotechnology, operating out of Pompano Beach, received equity investments from NIAMS and National Institutes of Health.

Company Overview

Contact Information

Company Background Information

Overview

Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo's lead program, AMP-101 (AAV-Dok7), was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

5/29/2023

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Patricio Sepulveda

        

President

Al Hawkin

        

Company Investors

• NIAMS
• National Institutes of Health

Browse more funded tech companies:

Amplitude | AMPLY Discovery

Share this article

About Our Venture Capital Transactions Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary